CRDL:CC News and Press, Cardiol Therapeutics Inc. From 08/09/23

Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment...

Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...

Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatme...

Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatme...

Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly ...

Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue Data Presented at The American College of Cardiology's 72 nd Annual Scientific Session Together with the World Congress of C...

(NewsDirect) Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in patients with recurrent pericarditis. Elsley told Proactive the study is designed to evaluate i...

The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and cl...

(NewsDirect) Contact Details Proactive Canada Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com Copyright (c) 2022 TheNewswire - All rights reserved.

The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit Participants Initiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - December 12, 2022) - Cardiol Therapeutics Inc. ( NASDA...